title: Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
abstract: Abundant interferon-γ secretion, potent cytotoxicity, and major histocompatibility complex-independent targeting of a large spectrum of tumors make γδ T cells attractive mediators of cancer immunotherapy. However, a better understanding of the molecular mechanisms involved in tumor cell recognition and γδ T-cell activation is required to improve the limited success of γδ T-cell-mediated treatments. Here, we review key advances in basic knowledge made over the past 3 years, and summarize the results of γδ T-cell-based clinical trials concluded to date. We also highlight new research directions on the basis of the modulation of receptors that control the function of γδ T cells.
authors.affiliation: Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
authors.forename: Anita Q
authors.initials: AQ
authors.lastname: Gomes
authors.forename: Duarte S
authors.initials: DS
authors.lastname: Martins
authors.forename: Bruno
authors.initials: B
authors.lastname: Silva-Santos
mesh_terms: D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000819:agonists / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism*
chemical_list: D016692:Receptors, Antigen, T-Cell, gamma-delta